Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E35.36 EPS (ttm)2.33 Insider Own0.10% Shs Outstand2.60B Perf Week0.88%
Market Cap214.11B Forward P/E15.70 EPS next Y5.24 Insider Trans-39.98% Shs Float2.58B Perf Month3.08%
Income6.22B PEG3.61 EPS next Q1.06 Inst Own78.40% Short Float1.54% Perf Quarter11.55%
Sales42.29B P/S5.06 EPS this Y27.80% Inst Trans-0.18% Short Ratio3.46 Perf Half Y17.59%
Book/sh10.21 P/B8.06 EPS next Y11.97% ROA7.30% Target Price85.49 Perf Year50.47%
Cash/sh3.41 P/C24.16 EPS next 5Y9.81% ROE19.90% 52W Range52.83 - 83.45 Perf YTD7.70%
Dividend2.20 P/FCF68.30 EPS past 5Y9.60% ROI11.20% 52W High-1.31% Beta0.65
Dividend %2.67% Quick Ratio0.90 Sales past 5Y-0.80% Gross Margin68.10% 52W Low55.90% ATR1.11
Employees69000 Current Ratio1.20 Sales Q/Q5.40% Oper. Margin19.60% RSI (14)66.66 Volatility1.48% 1.36%
OptionableYes Debt/Eq0.94 EPS Q/Q21.20% Profit Margin14.70% Rel Volume0.48 Prev Close82.29
ShortableYes LT Debt/Eq0.74 EarningsMay 03 BMO Payout82.00% Avg Volume11.48M Price82.36
Recom1.80 SMA201.30% SMA505.18% SMA20014.86% Volume3,541,596 Change0.09%
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Mar-25-19 10:53AM  S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion PR Newswire
07:10AM  Report: Exploring Fundamental Drivers Behind ON Semiconductor, Pilgrim's Pride, Merck & Co., Healthcare Services Group, Genomic Health, and Spectrum Pharmaceuticals New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-24-19 09:45AM  Investors Who Bought Merck (NYSE:MRK) Shares Three Years Ago Are Now Up 55% Simply Wall St.
Mar-23-19 12:14PM  3 Cancer Treatment Stocks to Buy in March Motley Fool
Mar-21-19 10:10AM  Merck's Keytruda Picks Up Pace in Thriving Anti-PD-L1 Market Zacks
10:03AM  Bristol-Myers' Celgene Buyout Still Uncertain Amid Opposition Zacks
Mar-20-19 09:15PM  Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $15. ... GuruFocus.com
04:05PM  BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering GlobeNewswire
03:17PM  Invest in Americas Rising Healthcare Costs With These Stocks InvestorPlace
11:30AM  Pfizer/Merck KGaA End Bavencio+Talzenna Ovarian Cancer Study Zacks
10:43AM  Glaxo Presents Encouraging Data on Endometrial Cancer Drug Zacks
09:00AM  Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development Business Wire
06:30AM  Merck and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022 Business Wire
Mar-19-19 06:18PM  [$$] If This Is Failure, Show Me Success The Wall Street Journal
05:45PM  Merck (MRK) Gains As Market Dips: What You Should Know Zacks
03:00PM  Post-GSK purchase, Tesaro readies for cancer clash with Merck American City Business Journals
12:00PM  The Zacks Analyst Blog Highlights: Merck, Adobe, Broadcom, AstraZeneca and Ross Stores Zacks
11:56AM  Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer Zacks
10:21AM  Why You Should Buy ABBV Stock for Income and Value InvestorPlace
Mar-18-19 10:34PM  U.S. FDA approves Roche's small cell lung cancer treatment Reuters
01:15PM  Top Research Reports for Merck, Adobe & Broadcom Zacks
11:47AM  IMMUNE DESIGN CORP. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger GlobeNewswire
09:01AM  The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J Zacks
08:06AM  AstraZeneca Up This Year on New Drugs & Pipeline Progress Zacks
08:00AM  New Treatment Option Now Available in Canada for Newly Diagnosed Patients with Advanced Lung Cancer CNW Group
Mar-15-19 11:28AM  Merck's Keytruda Gets EU Approval for Difficult Lung Cancer Zacks
10:31AM  Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others Zacks
Mar-14-19 09:23AM  Thursdays Vital Data: Aurora Cannabis, Roku and Merck InvestorPlace
06:45AM  European Commission Approves Mercks KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Business Wire
Mar-13-19 05:45PM  Merck (MRK) Gains But Lags Market: What You Should Know Zacks
01:10PM  Lilly's Cyramza Successful in Phase III First-Line NSCLC Study Zacks
08:37AM  FDA medical adviser: 'Congress is owned by pharma' Yahoo Finance
Mar-12-19 02:06PM  BioNtech hires banks for IPO worth up to $800 million - sources Reuters
01:29PM  Biontech stock offering could be worth as much as $800 million-sources Reuters
12:06PM  Merck KGaA calls on Versum investors to vote down Entegris merger Reuters
10:01AM  Pfizer's (PFE) Kidney Cancer Drug Combo Gets EMA's Validation Zacks
09:15AM  Why Merck (MRK) is a Great Dividend Stock Right Now Zacks
Mar-11-19 12:58PM  Seres teams up with AstraZeneca to explore microbiome benefits in cancer treatment American City Business Journals
10:06AM  The Zacks Analyst Blog Highlights: J&J, Lilly, Pfizer, AstraZeneca and Merck's Zacks
Mar-08-19 01:45PM  Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs Zacks
10:36AM  Versum, Entegris see extra merger benefits, Merck hires Goldman Reuters
09:35AM  Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC Zacks
06:05AM  Merck KGaA mandates Goldman as additional advisor for Versum deal Reuters
03:28AM  [$$] Kings and Wellcome sign US deal to develop painkillers Financial Times
Mar-07-19 07:39AM  Merck KGaA encouraged by market reaction to Versum swoop Reuters
06:30AM  BriaCell Therapeutics Corp. Highlights Recent Clinical and Scientific Achievements in Exclusive Audio Interview with NetworkNewsWire GlobeNewswire
06:13AM  Should You Be Excited About Merck & Co., Inc.s (NYSE:MRK) 23% Return On Equity? Simply Wall St.
Mar-06-19 02:55PM  Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA Zacks
Mar-05-19 06:37PM  Merck Prices $5.0 Billion Debt Offering Business Wire
11:45AM  Merck & Co., Inc. -- Moody's assigns A1 rating to Merck's notes; stable outlook Moody's
11:43AM  Merck KGaA urges Versum shareholders to support takeover bid Reuters
08:42AM  Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda Zacks
06:45AM  Merck Begins Tender Offer to Acquire Immune Design Business Wire
06:44AM  Merck KGaA urges Versum shareholders to pipe up for rival bid Reuters
Mar-04-19 11:38PM  Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks Zacks
06:45AM  European Medicines Agency Adopts Positive Opinion for Mercks KEYTRUDA® (pembrolizumab) for Six-Week Dosing Schedule Across All Current Monotherapy Indications Business Wire
Mar-01-19 02:20PM  Endo (ENDP) Q4 Earnings & Revenues Beat Estimates, Shares Up Zacks
01:25PM  Versum Materials rejects Merck KGaA's unsolicited offer Reuters
11:49AM  Intercept (ICPT) Up on Q4 Revenue Beat, NASH Study in Focus Zacks
11:09AM  Versum Materials rejects Merck KGaA's unsolicited offer Reuters
09:39AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q4 Zacks
08:45AM  LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion For Use in Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer Business Wire
Feb-28-19 02:28PM  Drug Price Debate: is Legislation Necessary? Yahoo Finance Video
10:59AM  Perrigo (PRGO) Q4 Earnings Miss, Sales Beat, Stock Down Zacks
07:10AM  Factors of Influence in 2019, Key Indicators and Opportunity within Franklin Resources, Heartland Express, Ameriprise Financial, Merck & Co., NGL Energy Partners LP, and ResMed New Research Emphasizes Economic Growth GlobeNewswire
Feb-27-19 08:01PM  [$$] Germanys Merck Makes $5.24 Billion Offer for Versum Materials The Wall Street Journal
06:11PM  [$$] Germany's Merck Makes $5.24 Billion Offer for Versum Materials The Wall Street Journal
05:06PM  Germany's Merck makes $5.9 bln counterbid for Versum Reuters
02:59PM  Here's Why Versum Materials Rose as Much as 18.3% Today Motley Fool
12:40PM  Versum Sticks With Merger Plan as German Merck Barges In Bloomberg
11:58AM  Germany's Merck makes $5.9 billion counterbid for Versum Reuters
11:20AM  The patent system keeps American drug prices so high Yahoo Finance Video
08:10AM  Merck KGaA offers to buy Versum Materials in all-cash deal valued at $5.9 billion MarketWatch
07:15AM  AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study Zacks
Feb-26-19 08:14PM  Codexis Inc (CDXS) Q4 2018 Earnings Conference Call Transcript Motley Fool
06:16PM  Lawmakers grill top pharma execs over high drug costs CNBC Videos
02:48PM  Drugmakers CEOs clash with senators in hearing on drug price hikes MarketWatch
02:02PM  5 Stock Charts Ripe for a Breakout InvestorPlace
01:42PM  The Latest: Senators urge pharma CEOs to rein in lobbyists Associated Press
12:07PM  Senators say will support Judiciary panel if it looks into drug patents Reuters
10:15AM  Pharma execs offer Senate ideas to lower drug costs except actually cutting prices CNBC
09:45AM  Drugmakers CEOs set to get grilled at Senate hearing on rising drug prices MarketWatch
06:55AM  LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as First-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer Business Wire
06:30AM  BriaCell Announces C$500,000 Equity Investment by BriaCell Director GlobeNewswire
02:30AM  AstraZeneca's Lynparza meets main goal of late-stage cancer study Reuters
Feb-25-19 05:54PM  Technician says it's time to fade the biotech rally CNBC Videos
10:03AM  The Zacks Analyst Blog Highlights: Walmart, Pfizer, Eli Lilly, Merck and Microsoft Zacks
09:59AM  The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie Zacks
08:56AM  Pharma M&A Wave: Spark Therapeutics, Clementia Pharma Among The Rare Disease Biotechs Acquired Benzinga
Feb-24-19 10:46AM  Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers GuruFocus.com
Feb-22-19 07:15PM  Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $7.7 million of Shares GuruFocus.com
05:08PM  Merck to Buy Immunotherapy Developer Immune Design for $300M Zacks
09:21AM  What's in the Cards for Perrigo (PRGO) This Earnings Season? Zacks
09:04AM  Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates Zacks
07:41AM  Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review Zacks
Feb-21-19 01:51PM  ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Immune Design Corp. PR Newswire
10:10AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Immune Design Corp. to Merck & Co., Inc. for $5.85 Per Share is Fair to Shareholders GlobeNewswire
09:28AM  Merck To Buy Immune Design For $300M Benzinga
09:12AM  Merck Gets Priority Review for Keytruda in Third-Line SCLC Zacks
08:20AM  Immune Design (IMDZ) Alert: Johnson Fistel Investigates Proposed Sale of Immune Design Corp.; Are Immune Design Shareholders Getting a Fair Deal? PR Newswire
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Pfizer Inc.; AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; IO Biotech; Premier Inc.; Cue Biopharma, Inc.; Foundation Medicine, Inc.; Daiichi Sankyo Company, Limited; Cold Genesys, Inc.; Kyn Therapeutics; Adlai Nortye Ltd.; Cocrystal Pharma, Inc.; and Instituto Butantan. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEOMar 20Option Exercise39.29192,7367,572,597990,451Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 20Sale82.05192,73615,813,372797,715Mar 20 06:49 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Option Exercise39.2918,725735,705816,440Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 13Sale82.0018,7251,535,454797,715Mar 14 06:38 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Option Exercise39.296,961273,498804,676Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 05Sale82.006,961570,809797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Option Exercise39.2913,144516,428810,859Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOMar 04Sale82.0113,1441,077,875797,715Mar 06 06:13 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Option Exercise39.2953,9612,120,128745,911Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Sale80.0253,9614,318,089691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Option Exercise39.2941,9921,649,866733,942Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Sale80.0041,9923,359,452691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Option Exercise39.2942,7001,677,683734,650Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Sale80.0242,7003,416,944691,950Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Option Exercise39.2992,9133,650,552784,863Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Sale80.0392,9137,436,162691,950Feb 19 05:35 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Option Exercise59.1664,6623,825,55180,837Feb 14 06:02 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale78.9664,6625,105,95116,175Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Option Exercise24.305,000121,5005,100Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Sale78.715,000393,548100Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Option Exercise38.1873,7272,815,241125,194Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Sale78.6273,7275,796,30651,467Feb 14 06:02 PM
BRUN LESLIE ADirectorFeb 08Option Exercise24.305,000121,5005,000Feb 11 05:33 PM
BRUN LESLIE ADirectorFeb 08Sale77.223,052235,6811,948Feb 11 05:33 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Option Exercise39.29231,5669,098,228923,516Feb 06 05:30 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Sale78.08231,56618,079,654691,950Feb 06 05:30 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Option Exercise44.98225,44310,140,426366,998Nov 08 04:31 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Sale75.27225,44316,967,967141,555Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise54.6836,2181,980,40082,481Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale75.1436,2182,721,34846,263Nov 08 04:31 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Option Exercise39.29277,87910,917,866277,879Nov 02 04:44 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Sale73.81277,87920,510,9450Nov 02 04:44 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Option Exercise58.3647,0362,745,21756,806Nov 01 05:07 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Sale74.3347,0363,496,1589,770Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Option Exercise34.1925,467870,71782,135Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Sale72.0025,4671,833,73956,668Nov 01 05:07 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Option Exercise36.56279,85010,231,316971,800Oct 03 05:26 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Sale72.07279,85020,168,258691,950Oct 03 05:26 PM
Merck & Co., Inc.10% OwnerOct 01Buy15.00666,6669,999,9902,723,509Oct 02 02:31 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Option Exercise36.56279,85110,231,353971,801Sep 19 05:43 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Sale70.08279,85119,611,818691,950Sep 19 05:43 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Option Exercise36.56100,0003,656,000100,000Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.187,360516,51155,406Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.18100,0007,017,7800Sep 18 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Option Exercise34.8629,2081,018,17680,675Aug 06 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Sale65.2029,2081,904,36251,467Aug 06 04:49 PM
Karachun Rita ASr. VP Fince-Global ControllerAug 02Sale65.015,000325,04016,175Aug 02 05:07 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Option Exercise33.49228,0917,638,768938,788Aug 01 05:12 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Sale65.00228,09114,826,691710,697Aug 01 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Option Exercise36.56100,0003,656,000100,000Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.0034,0942,079,78562,766Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.00100,0006,100,1600Jun 19 10:55 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 15Sale59.669,972594,96345,717May 16 12:33 PM
Watson AshleySVP Chief Ethics & Com OfficerMay 01Option Exercise0.0010,441012,783May 02 12:19 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 01Option Exercise0.004,009052,609May 02 12:18 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise0.003,007022,205May 02 12:18 PM
GRADDICK WEIR MIRIAN MExe V-P, HRApr 16Sale58.0024,0001,392,00080,433Apr 17 05:56 PM